CSL Limited (CSLLY)
USD 81.65
(0.89%)
USD 81.65
(0.89%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 18.62 Billion USD | -32.66% |
| 2023 | 18.4 Billion USD | 33.7% |
| 2022 | 13.76 Billion USD | 40.85% |
| 2021 | 9.77 Billion AUD | 9.38% |
| 2020 | 8.93 Billion AUD | 26.53% |
| 2019 | 7.06 Billion AUD | 5.5% |
| 2018 | 6.69 Billion AUD | 12.35% |
| 2017 | 5.95 Billion AUD | 19.29% |
| 2016 | 4.99 Billion AUD | 36.71% |
| 2015 | 3.65 Billion AUD | 17.28% |
| 2014 | 3.11 Billion AUD | 4.95% |
| 2013 | 2.96 Billion AUD | 21.32% |
| 2012 | 2.44 Billion AUD | 60.82% |
| 2011 | 1.52 Billion AUD | 19.69% |
| 2010 | 1.27 Billion AUD | -17.26% |
| 2009 | 1.53 Billion AUD | -14.97% |
| 2008 | 1.8 Billion AUD | 10.35% |
| 2007 | 1.63 Billion AUD | 0.49% |
| 2006 | 1.62 Billion AUD | 18.76% |
| 2005 | 1.37 Billion AUD | 8.97% |
| 2004 | 1.25 Billion AUD | 99.51% |
| 2003 | 631.24 Million AUD | 7.91% |
| 2002 | 584.95 Million AUD | 27.96% |
| 2001 | 457.15 Million AUD | 400.78% |
| 2000 | 91.28 Million AUD | -6.73% |
| 1999 | 97.87 Million AUD | 18.1% |
| 1998 | 82.87 Million AUD | -25.73% |
| 1997 | 111.58 Million AUD | 6.44% |
| 1996 | 104.83 Million AUD | 4.63% |
| 1995 | 100.2 Million AUD | 23.18% |
| 1994 | 81.34 Million AUD | 68.37% |
| 1993 | 48.31 Million AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 18.14 Billion USD | 0.0% |
| 2024 Q1 | 28.22 Billion USD | 53.31% |
| 2024 Q4 | 18.62 Billion USD | 0.0% |
| 2024 FY | 18.62 Billion USD | 1.16% |
| 2023 Q2 | 17.56 Billion USD | -36.04% |
| 2023 Q1 | 27.46 Billion USD | 99.48% |
| 2023 FY | 18.4 Billion USD | 33.7% |
| 2023 Q4 | 18.4 Billion USD | -33.15% |
| 2023 Q3 | 27.53 Billion USD | 56.75% |
| 2022 Q4 | 13.76 Billion USD | -25.17% |
| 2022 Q1 | 13.01 Billion USD | 33.15% |
| 2022 Q2 | 9.36 Billion USD | -28.02% |
| 2022 Q3 | 18.39 Billion USD | 96.38% |
| 2022 FY | 13.76 Billion USD | 40.85% |
| 2021 Q1 | 13.32 Billion USD | 2.3% |
| 2021 Q3 | 12.86 Billion USD | 35.52% |
| 2021 Q4 | 9.77 Billion AUD | -24.04% |
| 2021 FY | 9.77 Billion AUD | 9.38% |
| 2021 Q2 | 9.49 Billion USD | -28.71% |
| 2020 FY | 8.93 Billion AUD | 26.53% |
| 2020 Q3 | 14.77 Billion USD | 85.61% |
| 2020 Q4 | 13.02 Billion AUD | -11.88% |
| 2020 Q1 | 11.84 Billion USD | 67.71% |
| 2020 Q2 | 7.96 Billion USD | -32.79% |
| 2019 FY | 7.06 Billion AUD | 5.5% |
| 2019 Q3 | 9.94 Billion USD | 4.9% |
| 2019 Q1 | 9.24 Billion USD | 38.05% |
| 2019 Q2 | 9.48 Billion USD | 2.61% |
| 2019 Q4 | 7.06 Billion AUD | -29.0% |
| 2018 Q3 | 8.71 Billion USD | 3.71% |
| 2018 FY | 6.69 Billion AUD | 12.35% |
| 2018 Q1 | 8.36 Billion USD | 40.3% |
| 2018 Q2 | 8.4 Billion USD | 0.5% |
| 2018 Q4 | 6.69 Billion AUD | -23.18% |
| 2017 Q2 | 7.23 Billion USD | 6.07% |
| 2017 FY | 5.95 Billion AUD | 19.29% |
| 2017 Q4 | 5.95 Billion AUD | -23.6% |
| 2017 Q3 | 7.79 Billion USD | 7.76% |
| 2017 Q1 | 6.82 Billion USD | 36.59% |
| 2016 Q1 | 6.62 Billion USD | 81.23% |
| 2016 FY | 4.99 Billion AUD | 36.71% |
| 2016 Q3 | 6.49 Billion USD | 1.68% |
| 2016 Q2 | 6.39 Billion USD | -3.47% |
| 2016 Q4 | 4.99 Billion AUD | -23.14% |
| 2015 Q3 | 4.79 Billion USD | 11.21% |
| 2015 FY | 3.65 Billion AUD | 17.28% |
| 2015 Q1 | 4.02 Billion USD | 29.34% |
| 2015 Q2 | 4.3 Billion USD | 6.9% |
| 2015 Q4 | 3.65 Billion AUD | -23.73% |
| 2014 Q1 | 3.15 Billion USD | 6.12% |
| 2014 Q3 | 3.36 Billion USD | 2.06% |
| 2014 Q2 | 3.29 Billion USD | 4.51% |
| 2014 FY | 3.11 Billion AUD | 4.95% |
| 2014 Q4 | 3.11 Billion AUD | -7.28% |
| 2013 Q1 | 2.21 Billion USD | -9.38% |
| 2013 Q2 | 2.21 Billion USD | -0.06% |
| 2013 Q3 | 2.84 Billion USD | 28.18% |
| 2013 Q4 | 2.96 Billion AUD | 4.52% |
| 2013 FY | 2.96 Billion AUD | 21.32% |
| 2012 Q4 | 2.44 Billion AUD | 0.0% |
| 2012 FY | 2.44 Billion AUD | 60.82% |
| 2011 Q4 | 1.52 Billion AUD | 0.0% |
| 2011 FY | 1.52 Billion AUD | 19.69% |
| 2010 FY | 1.27 Billion AUD | -17.26% |
| 2010 Q4 | 1.27 Billion AUD | 0.0% |
| 2009 Q4 | 1.53 Billion AUD | 0.0% |
| 2009 FY | 1.53 Billion AUD | -14.97% |
| 2008 Q4 | 1.8 Billion AUD | 0.0% |
| 2008 FY | 1.8 Billion AUD | 10.35% |
| 2007 Q4 | 1.63 Billion AUD | 0.0% |
| 2007 FY | 1.63 Billion AUD | 0.49% |
| 2006 FY | 1.62 Billion AUD | 18.76% |
| 2006 Q4 | 1.62 Billion AUD | 0.0% |
| 2005 FY | 1.37 Billion AUD | 8.97% |
| 2005 Q4 | 1.37 Billion AUD | 0.0% |
| 2004 Q4 | 1.25 Billion AUD | 0.0% |
| 2004 FY | 1.25 Billion AUD | 99.51% |
| 2003 Q4 | 631.24 Million AUD | 0.0% |
| 2003 FY | 631.24 Million AUD | 7.91% |
| 2002 FY | 584.95 Million AUD | 27.96% |
| 2002 Q4 | 584.95 Million AUD | 0.0% |
| 2001 Q4 | 457.15 Million AUD | 0.0% |
| 2001 FY | 457.15 Million AUD | 400.78% |
| 2000 Q4 | 91.28 Million AUD | 0.0% |
| 2000 FY | 91.28 Million AUD | -6.73% |
| 1999 Q4 | 97.87 Million AUD | 0.0% |
| 1999 FY | 97.87 Million AUD | 18.1% |
| 1998 Q4 | 82.87 Million AUD | 0.0% |
| 1998 FY | 82.87 Million AUD | -25.73% |
| 1997 Q4 | 111.58 Million AUD | 0.0% |
| 1997 FY | 111.58 Million AUD | 6.44% |
| 1996 FY | 104.83 Million AUD | 4.63% |
| 1995 FY | 100.2 Million AUD | 23.18% |
| 1994 FY | 81.34 Million AUD | 68.37% |
| 1993 FY | 48.31 Million AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -67878003.015% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -196616.199% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -25594.416% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -2302216.783% |
| Rebus Holdings, Inc. | 5.24 Million USD | -355127.013% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -31453.503% |
| Qrons Inc. | 1.48 Million USD | -1250711.943% |
| Neon Bloom, Inc. | 1.22 Million USD | -1518477.931% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -24754.511% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -41661346.214% |
| Skye Bioscience, Inc. | 14.07 Million USD | -132224.453% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -34832.933% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -194232.678% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -4416980.993% |
| SQZ Biotechnologies Company | 50.03 Million USD | -37112.974% |
| Intellipharmaceutics International Inc. | 12 Million USD | -154961.714% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -483383.512% |
| Mesoblast Limited | 188.44 Million USD | -9781.417% |
| Marizyme, Inc. | 26.67 Million USD | -69705.075% |
| Genus plc | 485 Million USD | -3739.381% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -318609.702% |
| Pharming Group N.V. | 244.07 Million USD | -7529.275% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -926257.997% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -739906.867% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -489926.316% |
| ContraFect Corporation | 32.53 Million USD | -57140.786% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -939733.686% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -486386.741% |
| IMV Inc. | 37.93 Million USD | -48989.45% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -157997.23% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1151099938.945% |
| ONE Bio Corp. | 27.49 Million USD | -67623.046% |
| Accustem Sciences Inc. | 1.07 Million USD | -1725282.422% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -23952.857% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -880296.81% |
| Q BioMed Inc. | 8.13 Million USD | -228857.822% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -22352.523% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -361751.406% |
| Biomind Labs Inc. | 1.49 Million USD | -1242449.773% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -15584.512% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -205834.533% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -101082.308% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1298561.446% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -13104513.111% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -9258735.697% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -323979.013% |
| GB Sciences, Inc. | 5.41 Million USD | -343615.811% |
| Alpha Cognition Inc. | 7.16 Million USD | -259796.544% |
| HST Global, Inc. | 593.59 Thousand USD | -3136897.909% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -1478704.282% |
| Halberd Corporation | 728.71 Thousand USD | -2555205.955% |
| Enzolytics Inc. | 365.26 Million USD | -4997.886% |
| Agentix Corp. | 2.51 Million USD | -741608.507% |
| Resverlogix Corp. | 67.39 Million USD | -27529.236% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -2220037.064% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | -4084.955% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -1086306.068% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -75148.443% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -156338.226% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -507953.664% |
| AVAX Technologies, Inc. | 3.99 Million USD | -466154.105% |
| Zenith Capital Corp. | 27.56 Thousand USD | -67543155.105% |
| Genscript Biotech Corporation | 1.32 Billion USD | -1304.434% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -7802409.072% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -498546.87% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -2734927.922% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -686605.947% |
| Kadimastem Ltd | 3.5 Million USD | -531189.775% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -27821920.35% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -36946.395% |
| BioStem Technologies, Inc. | 15.9 Million USD | -116978.842% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -4007009.979% |
| LadRx Corporation | 2.2 Million USD | -846106.001% |
| Cell Source, Inc. | 15.8 Million USD | -117704.371% |
| Regen BioPharma, Inc. | 5.45 Million USD | -341092.931% |
| Regen BioPharma, Inc. | 5.45 Million USD | -341092.931% |
| NovAccess Global Inc. | 7.86 Million USD | -236786.336% |
| Affymax, Inc. | 8.87 Million USD | -209808.691% |
| Itoco Inc. | 1.65 Million USD | -1126294.383% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -907548.551% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -307736.006% |
| Mobile Lads Corp. | 1.31 Million USD | -1417565.971% |
| CytoDyn Inc. | 127.89 Million USD | -14459.714% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -44548812.653% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1188694.269% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -168487.712% |
| SYBLEU INC | 681.41 Thousand USD | -2732603.955% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -305066.993% |
| International Stem Cell Corporation | 5.27 Million USD | -352770.949% |
| Bioxytran, Inc. | 3.24 Million USD | -572942.006% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -2975408.502% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -403202.921% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -45321.505% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -83533.506% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -919279.852% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -339823.33% |
| Neutra Corp. | 973.52 Thousand USD | -1912631.927% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -64077.15% |
| PureTech Health plc | 125.58 Million USD | -14727.644% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -495518.325% |
| IXICO plc | 1.9 Million USD | -979802.036% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -90605.831% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -17921.95% |
| CSL Limited | 18.62 Billion USD | 0.0% |
| Cellectis S.A. | 249.36 Million USD | -7367.235% |